Background: Little is known about the epidemiology of prostate cancer in Iranian men. We carried out an active prostate cancer surveillance program in five provinces of Iran.
Methods: Data used in this study were obtained from population-based cancer registries between 1996 and 2000.
Results: The age-standardized incidence rate of prostate carcinoma in the five provinces was 5.1 per 100,000 person-years. No significant difference was seen in the age-standardized incidence rate of prostate cancer within the provinces studied. The mean+/-SD age of patients with prostate cancer was 67+/-13.5 years.
Conclusion: The incidence of prostate cancer in Iran is very low as compared to the Western countries. This can partly be explained by lack of nationwide screening program, younger age structure and quality of cancer registration system in Iran.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Omega-3 Docosahexaenoic Acid as a Promising Inducer of Ferroptosis: Dynamics of Action in Prostate and Colorectal Cancer Models.
Dokl Biochem Biophys
January 2025
National Research University Higher School of Economics, Moscow, Russia.
Ferroptosis is an iron-dependent form of programmed cell death (PCD) associated with lipid membrane peroxidation. It has gained attention in cancer research because some tumor cells that are resistant to other forms of PCD are sensitive to ferroptosis. Despite the significant amount of research on ferroptosis, the list of known inducers remains limited, creating opportunities to discover new compounds with clinical potential.
View Article and Find Full Text PDFExhalation of Rn-219 by patients treated with Radium-223.
EJNMMI Phys
January 2025
Department for Radiation Protection and Medical Physics, Hannover Medical School, Carl-Neuberg- Str. 1, 30625, Hannover, Germany.
Background: Treatment with Ra-223 dichloride is approved for the therapy of castration resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastases in Europe since 2013, and Ra-223 is under discussion for labelling other molecules and nanoparticles. The direct progeny of Ra-223 is Rn-219, also known as actinon, a radioactive noble gas with a half-life of 3.98 s.
View Article and Find Full Text PDFCorrection: Radiopharmacokinetic modelling and radiation dose assessment of Ra used for treatment of metastatic castration-resistant prostate cancer.
EJNMMI Phys
January 2025
Institute of Radiation Medicine, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764, Neuherberg, Germany.
Prognostic F-flotufolastat PET parameters for outcome assessment of Lu-labeled PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine, School of Medicine, Technical University of Munich, Munich, Germany.
Purpose: This retrospective analysis evaluates baseline F-flotufolastat positron emission tomography (PET) parameters as prognostic parameters for treatment response and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing treatment with [Lu]Lu-PSMA-I&T.
Methods: A total of 188 mCRPC patients with baseline F-flotufolastat PET scans were included. Tumor lesions were semiautomatically delineated, with imaging parameters including volume-based and standardized uptake value (SUV)-based metrics.
Targeting CD44 and EpCAM with Antibody Dye Conjugates for the Photoimmunotherapy of Prostate Cancer.
Antibodies (Basel)
January 2025
Department of Urology, Medical Center-University of Freiburg, 79106 Freiburg im Breisgau, Germany.
Background/objectives: Photoimmunotherapy (PIT) is an innovative approach for the targeted therapy of cancer. In PIT, photosensitizer dyes are conjugated to tumor-specific antibodies for targeted delivery into cancer cells. Upon irradiation with visible light, the photosensitizer dye is activated and induces cancer-specific cell death.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!